Drug intelligence / Profile preview

TB-M002

Development stage: Preclinical
Lead developer: Therabene
Modality: Small Molecules

Overview

TB-M002 is a preclinical-stage small molecule inhibitor targeting the c-Myc (MYC) transcription factor. Developed by Therabene, the compound is designed to disrupt the activity of c-Myc, a master regulator of cell growth, metabolism, and apoptosis that is frequently overexpressed or dysregulated in a wide variety of human cancers. By inhibiting the transcriptional activity or protein-protein interactions of c-Myc, TB-M002 aims to suppress tumor cell proliferation and survival. The program is currently in early preclinical development for the treatment of oncology indications.

Other names: TB-M002TB-M-002TB-M 002

Targets

MYC (MYC proto-oncogene protein)

Beyond the preview

Go deeper on TB-M002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-M002.

Explore the full profile